Program areas at JDRF
Research funding - for the year ended june 30, 2024, Breakthrough T1D (formerly jdrf) directly funded research grants and industry agreements for which $103.5 million in research grant expense, net was recognized according to gaap in addition to $18 million of programmatic research investments that are recorded on Breakthrough T1D's balance sheet. For an expanded description of program service activities related to direct research funding, see schedule o.
Public education and outreach - Breakthrough T1D (formerly jdrf) educates the community about type 1 diabetes (T1D) and its complications and provides support services and resources to newly diagnosed children and adults, their families, and others. For an expanded description of program service activities related to public education and outreach, see schedule o.
Research support - Breakthrough T1D (formerly jdrf) maintains an in-house team of skilled scientific, medical, policy, and government relations professionals who play a critical role in leading and supporting the evaluation of research funding opportunities by Breakthrough T1D and influencing research direction and the disbursement of research funds from others. These professionals also work with regulatory and policy officials to ensure that research can proceed without delay and results are understood by healthcare decision makers. For an expanded description of program service activities related to research support, see schedule o.
Who funds Breakthrough T1D (JDRF)
Grants from foundations and other nonprofits
Personnel at JDRF
| Name | Title | Compensation | Date of data |
|---|
| Aaron J. Kowalski | Chief Executive Officer | $861,917 | 2025-06-18 |
| Derek Rapp | Board Member | $800,000 | 2024-11-07 |
| Elizabeth A. Mily | Chief Executive Officer, T1D Fund | | 2025-06-18 |
| Rob King | Chief Financial and Administrative Officer | | 2024-11-07 |
| Tashni-Ann Dubroy, Ph.D. | Chief Operating Officer | | 2025-06-18 |
| ...and 18 more key personnel |
Financials for JDRF
| Revenues | FYE 06/2024 | FYE 06/2023 | % Change |
|---|
| Total grants, contributions, etc. | $211,575,057 | $190,086,200 | 11.3% |
| Program services | $21,841,702 | $19,620,834 | 11.3% |
| Investment income and dividends | $12,063,436 | $7,848,897 | 53.7% |
| Tax-exempt bond proceeds | $0 | $0 | - |
| Royalty revenue | $1,246,568 | $155,220 | 703.1% |
| Net rental income | $50,669 | $54,122 | -6.4% |
| Net gain from sale of non-inventory assets | $11,099,934 | $1,383,582 | 702.3% |
| Net income from fundraising events | $5,496,750 | $0 | 999% |
| Net income from gaming activities | $471,660 | $800,383 | -41.1% |
| Net income from sales of inventory | $0 | $0 | - |
| Miscellaneous revenues | $-5,730,319 | $3,848,847 | -248.9% |
| Total revenues | $258,115,457 | $223,798,085 | 15.3% |
Organizations like JDRF
| Organization | Type | Location | Revenue |
|---|
| Ludwig Institute for Cancer Research | 501(c)(3) | New York, NY | $72,893,952 |
| American Heart Association (AHA) | 501(c)(3) | Dallas, TX | $972,755,203 |
| Cystic Fibrosis Foundation | 501(c)(3) | Bethesda, MD | $292,016,280 |
| National Organization for Rare Disorders (NORD) | 501(c)(3) | Quincy, MA | $66,397,453 |
| American Cancer Society (ACS) | 501(c)(3) | Atlanta, GA | $656,838,115 |
| National Multiple Sclerosis Society | 501(c)(3) | New York, NY | $171,750,637 |
| Susan G Komen | 501(c)(3) | Dallas, TX | $102,934,186 |
| The Leukemia and Lymphoma Society | 501(c)(3) | Washington, DC | $368,242,059 |
| American Association for Cancer Research | 501(c)(3) | Philadelphia, PA | $74,316,369 |
| National Marrow Donor Program (NMDP) | 501(c)(3) | Minneapolis, MN | $577,983,771 |
Data update history
June 19, 2025
Updated personnel
Identified 2 new personnel
May 29, 2025
Posted financials
Added Form 990 for fiscal year 2024
May 26, 2025
Updated personnel
Identified 3 new personnel
May 26, 2025
Used new vendors
Identified 1 new vendor, including
Nonprofit Types
Grantmaking organizationsDisease research fundraisersMedical research organizationsHeadquarter / parent organizationsCharities
Issues
HealthDiseases and disorders
Characteristics
Political advocacyProvides grantsConducts researchLobbyingFundraising eventsOperates internationallyNational levelEndowed supportCommunity engagement / volunteeringGala fundraisersTax deductible donationsAccepts online donations
General information
- Address
- 200 Vesey St 28th Floor
- New York, NY 10281
- Metro area
- New York-Newark-Jersey City, NY-NJ-PA
- County
- New York County, NY
- Website URL
- breakthrought1d.org/greaternymetro/Â
- Phone
- (800) 533-2873
- Facebook page
- myJDRFÂ
- Twitter profile
- @jdrfÂ
IRS details
- EIN
- 23-1907729
- Fiscal year end
- June
- Taxreturn type
- Form 990
- Year formed
- 1970
- Eligible to receive tax-deductible contributions (Pub 78)
- Yes
Categorization
- NTEE code, primary
- H30: Cancer Research
- NAICS code, primary
- 813212: Health and Disease Research Fundraising Organizations
- Parent/child status
- Independent
California AB-488 details
- AB 488 status
- May Operate or Solicit for Charitable Purposes
- Charity Registration status
- Current
- FTB status revoked
- Not revoked
- AG Registration Number
- 015887
- FTB Entity ID
- 0719684
- AB 488 data last updated ("as-of") date
- 2025-07-02
Free account sign-up
Want updates when JDRF has new information, or want to find more organizations like Breakthrough T1D (JDRF)?
Create free Cause IQ account